Insider selling
Traded Sep 22 · filed 58 days laterNot reported under a pre-arranged trading plan
A major shareholder of Bioaffinity Technologies sold $61K of Bioaffinity Technologies shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Sep 30, 2026 · Filed Nov 19, 2026
A major shareholder of Bioaffinity Technologies paid $82K out of pocket for Bioaffinity Technologies shares. Shares held went up 11% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$82,177
Shares × reported transaction price
$25K–$100K
+10.6%
HRT FINANCIAL LP, 10% owner's past purchases, 90 days after disclosure: 75 buys, median −73.7 pts vs S&P 500, beat it 7 of 75 times. Past results, not a forecast.
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 0 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 9 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
54 days after results of Aug 7, 2026, 37 days before results of Nov 6, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $6.56 on Sep 30, 2026, 44% above its 52-week low and 91% below its high, after an 8% drop over the previous 30 trading days
52-week range $4.56 (Aug 31, 2026) to $71.10 (Mar 26, 2026), 3% of the way up, from 246 adjusted closes. 30 trading days earlier: $7.10 on Aug 18, 2026. Describes the past only, not a forecast
RSI 45, 69% under its 200-day average, 17% under its 50-day average, 91% below the 52-week high, 20-day volatility 366% a year, against the S&P 500: +44 points over 1 month, −50 points over 3 months, −106 points over 6 months
From the adjusted closes up to Sep 30, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
Insider selling
Traded Sep 22 · filed 58 days laterNot reported under a pre-arranged trading plan
A major shareholder of Bioaffinity Technologies sold $61K of Bioaffinity Technologies shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Sep 23 · filed 57 days laterNot reported under a pre-arranged trading plan
A major shareholder of Bioaffinity Technologies sold $88K of Bioaffinity Technologies shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
Traded Sep 23 · filed 57 days laterNot reported under a pre-arranged trading plan
A major shareholder of Bioaffinity Technologies sold $88K of Bioaffinity Technologies shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.